October 18, 2021, ACROBiosystems announced that it has been listed on the Shenzhen Stock Exchange (Stock code: 301080). As the issuer's advisor, Llinks provided legal services for this IPO issuance.
Exploring the forefront of global biotechnology, ACROBiosystems has developed a number of core technologies and obtained patent authorization, providing recombinant protein and other key biological reagent products and technical services, helping global biomedical companies, biotechnology companies and scientific research institutions in the research and development and production of biological drugs, cellular immunotherapy and diagnostic reagents. ACROBiosystems' catalog includes a comprehensive list of disease-associated biomarkers and drug targets from human and other common species, used for early drug discovery and verification, drug screening and optimization, diagnostic reagent development and optimization, preclinical experiments and clinical trials for tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases. The drug production process and process control (CMC) and other R&D and production links, customers cover the global top 20 pharmaceutical companies such as Johnson & Johnson, Pfizer, Novartis, Gilead, Roche, Merck, etc. Aside from ACROBiosystems, the company also created other brands such as bioSeedin, ACRODiagnostics, and etc. which have established significant brand influence globally.
